We are currently preparing to initiate a global Phase III clinical trial to be conducted under the review of the U.S. FDA. We have named this study “Beacon-BTC” in the hope that it will serve as a beacon of light for patients with biliary tract cancer.

We will evaluate safety, tolerability, pharmacokinetics, etc. in a large-scale Phase 1 study, which will be the cornerstone of future global development.